Drug Profile
Abacavir/dolutegravir/lamivudine - ViiV Healthcare
Alternative Names: 572-Trii; Abacavir/GSK-1349572/lamivudine; Dolutegravir-Trii; Dolutegravir/abacavir/lamivudine; DTG/ABC/3TC; DTG/ABC/3TC FDC; GSK-1349572/abacavir/lamivudine; Lamivudine/abacavir/GSK-1349572; Triumeq; Triumeq PDLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Shionogi ViiV Healthcare LLC
- Developer GSK; Shionogi ViiV Healthcare LLC; ViiV Healthcare
- Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action HIV integrase inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 04 Jan 2023 Preregistration for HIV infections (In adolescents, In adults, In children) in European Union (PO) (3745769; 9377359)
- 16 Dec 2022 Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion of HIV-infection in European union (3743358; 9377359)
- 25 Sep 2022 Pharmacokinetics data from a phase I trial in HIV infections presented at the 2022 American College of Clinical Pharmacology Annual Meeting (ACCP-2022)